Sudha Thangirala, Godugu Kavitha, Glinsky Gennadi V, Mousa Shaker A
The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY 12144, USA.
Institute of Engineering in Medicine, University of California, San Diego, CA 92093, USA.
Biomedicines. 2022 Mar 29;10(4):795. doi: 10.3390/biomedicines10040795.
Thyroid hormone L thyroxine stimulates pancreatic carcinoma cell proliferation via thyrointegrin αvβ3 receptors, and antagonist tetraiodothyroacetic acid (tetrac) inhibits cancer cell growth. Chemically modified bis-triazole-tetrac conjugated with polyethylene glycol (P-bi-TAT) has higher binding affinity to αvβ3 receptors compared to tetrac. We investigated the antiproliferation effect of P-bi-TAT in pancreatic cancer cells (SUIT2) and its radio- and chemo-sensitizing roles in a mouse model of pancreatic cancer. P-bi-TAT treatment increased tumor-targeted radiation-induced cell death and decreased tumor size. P-bi-TAT acted as a chemo-sensitizer and enhanced the 5-fluorouracil (5FU) effect in decreasing pancreatic tumor weight compared to 5FU monotherapy. Withdrawal of treatment continued the tumor regression; however, the 5FU group showed tumor regrowth. The mechanisms of the anti-cancer activity of P-bi-TAT on SUIT2 cells were assessed by microarray experiments, and genome-wide profiling identified significant alterations of 1348 genes' expression. Both down-regulated and up-regulated transcripts suggest that a molecular interference at the signaling pathway-associated gene expression is the prevalent mode of P-bi-TAT anti-cancer activity. Our data indicate that non-cytotoxic P-bi-TAT is not only an anti-cancer agent but also a radio-sensitizer and chemo-sensitizer that acts on the extracellular domain of the cell surface αvβ3 receptor.
甲状腺激素L-甲状腺素通过甲状腺整合素αvβ3受体刺激胰腺癌细胞增殖,而拮抗剂四碘甲状腺乙酸(tetrac)抑制癌细胞生长。与tetrac相比,化学修饰的双三唑 - tetrac与聚乙二醇偶联物(P-bi-TAT)对αvβ3受体具有更高的结合亲和力。我们研究了P-bi-TAT在胰腺癌细胞(SUIT2)中的抗增殖作用及其在胰腺癌小鼠模型中的放射增敏和化疗增敏作用。P-bi-TAT治疗增加了肿瘤靶向性辐射诱导的细胞死亡并减小了肿瘤大小。与5-氟尿嘧啶(5FU)单药治疗相比,P-bi-TAT作为化疗增敏剂增强了5FU降低胰腺肿瘤重量的效果。停止治疗后肿瘤持续消退;然而,5FU组出现肿瘤复发。通过微阵列实验评估了P-bi-TAT对SUIT2细胞抗癌活性的机制,全基因组分析确定了1348个基因表达的显著变化。下调和上调的转录本均表明,对信号通路相关基因表达的分子干扰是P-bi-TAT抗癌活性的主要模式。我们的数据表明,非细胞毒性的P-bi-TAT不仅是一种抗癌剂,而且是一种作用于细胞表面αvβ3受体胞外域的放射增敏剂和化疗增敏剂。